Elacridar as an ADC Efficacy Enhancer
in Oncology Combinations

ADC Resistance: Efflux Pumps Are the Silent Killer

Antibody-drug conjugates (ADCs) are one of oncology's most exciting modalities — a $11.9 billion market in 2024 on its way to $30+ billion by 2033. But despite the elegant targeting mechanism, most patients who initially respond eventually relapse. The reasons are multifactorial, but one of the most clinically validated and mechanistically tractable involves the ABC transporter superfamily.

The ADC workflow is deceptively simple: antibody binds to tumour antigen → complex is internalised → lysosomal degradation releases free cytotoxic payload inside the cell → payload kills the cell. The problem is step four. If a cancer cell overexpresses P-glycoprotein (P-gp/ABCB1), BCRP (ABCG2), or MRP1 (ABCC1), the free payload is actively pumped back out before it can cause fatal DNA damage. The tumour effectively ejects its own chemotherapy.

A 2025 high-throughput screen of 27 common ADC payloads across P-gp-, ABCG2- and MRP1-expressing cell lines made this concrete: MMAE, DM1, DM4, and calicheamicin γ1 are all confirmed avid P-gp substrates. Every single pyrrolobenzodiazepine (PBD) dimer tested was a substrate of all three transporters. This is not a fringe concern — these payloads underpin the majority of approved ADCs.

Elacridar (GF120918): A Potent, Dual-Transporter Inhibitor With a Solved Bioavailability Problem

Elacridar is arguably the best-in-class small molecule inhibitor of both P-gp (IC₅₀ ~193 nM) and BCRP. Unlike first-generation modulators (verapamil, cyclosporin A) which had unacceptable toxicity and narrow therapeutic windows, elacridar is highly selective and does not meaningfully inhibit cytochrome P450 enzymes in vitro — a critical differentiator for combination use.

Historically, elacridar's development was stalled by a single pharmacological problem: it is practically insoluble in water. The crystalline formulation gave poor, unpredictable oral absorption. This is the central scientific problem that, once solved, unlocks the entire commercial thesis.

That problem is now solved. An amorphous solid dispersion (ASD) tablet formulation — elacridar HCl in a povidone K30/SDS matrix — achieves 16.9× higher in vitro dissolution than the crystalline form and has been evaluated clinically at doses of 25, 250, and 1,000 mg. At 250 mg, the ASD formulation achieved target Cmax ≥200 ng/mL (the plasma level associated with meaningful transporter inhibition in prior clinical work). The ASD formulation is stable for 12 months across storage conditions. This is the bioavailability breakthrough that changes the equation.

Source: Systematic HTS screen of 27 ADC payloads, published 2025 (PMC12883344). DXd payload used in Enhertu was deliberately engineered to avoid ABC-transporter substracy.

Priority ADC Combinations for Elacridar Co-development

Selection criteria: (1) payload confirmed P-gp substrate, (2) clinical evidence linking efflux to resistance, (3) large established market or rapidly growing indication, (4) unmet need in relapsed/refractory settings where P-gp upregulation is highest, (5) feasibility of a fixed-dose combination or standardised co-administration protocol.

Where Elacridar Adds No Value

How to Build This as a Business

The Biomarker-First Development Thesis

The single biggest mistake prior P-gp inhibitor programmes made was treating all comers. Trials of valspodar and zosuquidar with chemotherapy largely failed because they enrolled unselected patients — only a fraction of whom had P-gp-driven resistance. The lesson is clear: this programme must be biomarker-selected from day one.

ABCB1 expression (IHC or qRT-PCR on tumour biopsy) or P-gp functional phenotype (ex vivo rhodamine exclusion assay on circulating blasts in AML) should gate patient entry. This is both scientifically correct and commercially astute — it creates a companion diagnostic opportunity and positions the combination as precision medicine rather than a broad adjunct.

Commercial Structure Options

My preferred structure: build the co-administration label first (fastest path to proof-of-concept and market), then negotiate an FDC partnership with the ADC manufacturer once the clinical signal is confirmed. The elacridar ASD formulation patent is the core IP asset — protect it fiercely and consider formulation improvements (e.g., nanoparticle dispersion, self-emulsifying drug delivery systems) as additional IP layers.

Honest Assessment of What Could Go Wrong

The Investment Thesis in Plain Terms

The data is compelling. A large fraction of approved ADCs use payloads (MMAE, DM1, DM4, calicheamicin) that are effluxed from tumour cells by P-glycoprotein. Tumour P-gp upregulation is a clinically validated, biomarker-measurable mechanism of ADC resistance. Elacridar is a potent, selective, dual P-gp/BCRP inhibitor with a solved bioavailability problem. The ASD formulation achieves ~17× greater dissolution than the crystalline form and has clinical PK data supporting adequate exposure at 250 mg oral dosing.

This is not a speculative hypothesis. It is a mechanistically driven repurposing opportunity with direct clinical validation of the target pathway (gemtuzumab + P-gp inhibitor trials), confirmed payload substracy data (2025 systematic screen), and a large addressable market across at least four major approved ADCs.

The playbook is: secure the ASD formulation IP → run a biomarker-selected Phase 1b/2 in ABCB1-high AML with gemtuzumab ozogamicin → use the signal to negotiate an FDC partnership with Roche for the Kadcyla programme → build towards the $2–5B commercial prize in HER2+ breast cancer.